Lupin is currently trading at Rs. 978.00, up by 17.10 points or 1.78% from its previous closing of Rs. 960.90 on the BSE.
The scrip opened at Rs. 970.00 and has touched a high and low of Rs. 978.00 and Rs. 962.75 respectively. So far 11345 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1003.00 on 03-Mar-2014 and a 52 week low of Rs. 606.20 on 09-Apr-2013.
Last one week high and low of the scrip stood at Rs. 992.85 and Rs. 933.05 respectively. The current market cap of the company is Rs. 43499.18 crore.
The promoters holding in the company stood at 46.75% while Institutions and Non-Institutions held 43.17% and 10.08% respectively.
Pharma Major Lupin has received US Food and Drug Administration (US FDA) nod for Pioglitazone Hydrochloride Tablets. Pioglitazone tablets are to treat high blood sugar associated with diabetes.
Earlier in March, the company received final approval for its Doxycycline Capsules USP, 50 mg, 75 mg, and 100 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Aqua Pharmaceuticals' Monodox Capsules 50 mg, 75 mg, and 100 mg.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
